Vertex’ VP of Global R&D and CSO to retire

Peter Mueller joined the company in 2003

Biotechnology company Vertex Pharmaceuticals, based in Cambridge, MA, US, has announced that Peter Mueller, Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company.

Mueller’s retirement will be effective from 31 October, following a transition period. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.

Jeffrey Chodakewitz, Vertex’s Senior Vice President of Global Medicines Development and Medical Affairs and Chief Medical Officer, will continue to oversee all global clinical development programmes and other related functions and will assume additional responsibility for Regulatory Affairs and Global Patient Safety.

Vertex expects to appoint a Head of Global Research to oversee its drug discovery efforts following Mueller’s retirement.

You may also like

Research & Development

Vertex and Moderna collaborate to develop mRNA Therapeutics for cystic fibrosis

Moderna will receive $40 million upfront, with potential for an additional $275m in milestones and royalty payments
Research & Development

Vertex and CRISPR Therapeutics to use gene editing technology to develop new treatments for genetic diseases

Vertex will take a US$30m stake in CRISPR and make an upfront payment of $75m
Research & Development

Pipeline advancements and asset acquisitions fuelled mid-cap biotech R&D spend in 2014

Combined R&D spend of 35 mid-cap biotech companies increased by nearly US$2bn to reach a total of $9.7bn in 2014
Media

Orphan drugs market offers many opportunities for drug development, says new study

Breakthrough therapies for rare diseases command premium prices, particularly if no alternatives exist
Finance

Vertex cuts 370 jobs as sales of its hepatitis C drug fall

US biotechnology firm will instead focus on future opportunities in cystic fibrosis medicines
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Regulatory

Cystic fibrosis – ivacaftor

Since the discovery of the gene responsible for cystic fibrosis, CFTR or cystic fibrosis transmembrane regulator gene, several mutations have been found that lead to the production of abnormal CFTR protein
Subscribe now